Literature DB >> 3499223

The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens.

S Sano1, Y Izumi, S Sugihara, H Nakajima, H Fujiwara, T Hamaoka.   

Abstract

C3H/He mice were inoculated i.v. with 10(6) heavily X-irradiated syngeneic X5563 plasmacytoma cells 3 times at 4 day intervals. When these mice received an appropriate immunization procedure consisting of i.d. inoculation of viable tumor cells plus the surgical resection of the tumor which enables i.v. nonpresensitized mice to produce anti-X5563 immunity, they failed to develop tumor-specific immunity. This was demonstrated by the abrogation in potential of spleen and lymph node cells to generate in vivo protective immunity. In contrast, the tumor mass from X5563 tumor-bearing mice which had received the i.v. presensitization contained comparable anti-X5563 tumor neutralizing activity to that obtained from the tumor mass from nonpresensitized, X5563 tumor-bearing mice. Such an in vivo protective immunity was revealed to be mediated by tumor-specific T cells. These results demonstrate the differential generation and antitumor capability of tumor infiltrating T cells and T cells in lymphoid organs from mice which are in the tumor-specific tolerant state. The results are discussed in the context of potential utilization of tumor infiltrating in vivo protective T cells to enhance the local tumor-specific immunity in tumor-specific tolerant mice.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499223     DOI: 10.1007/BF00199949

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.

Authors:  S Tomita; H Fujiwara; Y Yamane; S Sano; H Nakajima; Y Izumi; H Arai; Y Kawanishi; T Tsuchida; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1986-02

Review 2.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

3.  Evidence for in vivo protection against murine-sarcoma virus-induced tumors by T lymphocytes from immune animals.

Authors:  R M Gorczynski
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

4.  Study of the cellular immune response to Gross virus-induced lymphoma by the mixed lymphocyte-tumor interaction.

Authors:  M Glaser; R B Herberman; H Kirchner; J Y Djeu
Journal:  Cancer Res       Date:  1974-09       Impact factor: 12.701

5.  Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clones.

Authors:  H Fujiwara; S Sato; A Kosugi; M Fukuzawa; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 6.  The murine sarcoma virus-induced tumor: exception or general model in tumor immunology?

Authors:  J P Levy; J C Leclerc
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

7.  T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.

Authors:  J C Leclerc; H Cantor
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

8.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

9.  The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

Authors:  H Fujiwara; M Fukuzawa; T Yoshioka; H Nakajima; T Hamaoka
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

10.  Cell-mediated immune reaction against tumors induced by oncornaviruses. II. Nature of the effector cells in tumor-cell cytolysis.

Authors:  J C Leclerc; E Gomard; F Plata; J P Levy
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.